HoloMD has developed Dr. Holo™, an AI companion that conducts daily check-ins and micro-interventions with psychiatric patients, translating emotion, context, and behavior into concise, visit-ready insights for providers. Every interaction is reviewed by licensed clinicians, allowing the company to balance scalable automation with human oversight while remaining HIPAA and HITECH compliant. The platform is structured for Remote Therapeutic Monitoring (RTM) CPT reimbursement, turning previously uncompensated care into billable activity and creating new revenue streams for clinicians. In its first 15 months, HoloMD moved from concept to live revenue, validated RTM billing across multiple commercial payers, and received positive patient engagement and clinician feedback. Founded in July 2024 and headquartered in Rockville, Maryland, the company is built on 40 years of psychiatric expertise from founder Dr. Bruce Kehr and holds seven provisional patents, one utility patent pending, and three trademarks pending. Executive leadership includes Jim Pearson, whose prior healthcare exits total $450 million. HoloMD’s near-term plans center on expanding deployment of Dr. Holo into additional practices and markets while advancing its patent-pending platform.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025